Epidemiology of nontuberculous mycobacterial pulmonary disease in Europe and Japan by Delphi estimation

Schildkraut, Jodie A.; Gallagher, Jack R.; Morimoto, Kozo; Lange, Christoph; Haworth, Charles; Floto, R. Andres; Hoefsloot, Wouter; Griffith, David E.; Wagner, Dirk; Ntm-Net,

doi:10.1016/j.rmed.2020.106164

Cited by 30 publications

(33 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our criteria to query the drug dispensing databases were strict, given the well-known poor compliance (10% in five EU countries) with NTM-PD treatment guidelines (14) . The projections, too, are biased as they were based on studies from other countries and health systems (6,12,13,(15)(16)(17) . Nonetheless, we do provide a first assessment of NTM-PD annual prevalence in the Netherlands, which is between 2.3 and 5.9 patients / 100,000 inhabitants in the study period.…”

Section: Discussionmentioning

confidence: 99%

“…Studies in Denmark (period 2000-2010), Scotland (1997Scotland ( -2008, Germany (2014) and The United Kingdom (2006)(2007)(2008)(2009)(2010)(2011)(2012)(2013)(2014)(2015)(2016) have produced estimated annual prevalence rates of 2.43, 2.44, 3.3 and 6.4 cases per 100,000 per year respectively (2)(3)(4)(5) . Another study aimed at determining prevalence in five European countries estimated the prevalence to be 6.2 / 100,000 inhabitants in 2016 (6) . Like in many countries where rates of tuberculosis infection have decreased, the prevalence of NTM-PD in the Netherlands is thought to be increasing (7) .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The epidemiology of nontuberculous mycobacterial pulmonary disease in the Netherlands

Schildkraut

Zweijpfenning

Nap³

et al. 2021

ERJ Open Res

Self Cite

View full text Add to dashboard Cite

BackgroundNontuberculous mycobacteria (NTM) are emerging opportunistic pathogens of humans. Because NTM-PD is not a notifiable disease in Europe, the epidemiology of NTM-PD is not well known. However, the prevalence of NTM-PD is thought to be increasing, particularly in countries where tuberculosis rates have decreased. Here we aim to determine the prevalence of NTM-PD in the Netherlands.Annual prevalence estimates of NTM-PD in the Netherlands (2012–2019) were derived from four separate databases, including two drug dispensing databases, an ICD-10 code database and a hospitalisation database. Databases covered a fraction of the Dutch population and were extrapolated. In addition, annual NTM-PD prevalence was also estimated by means of a pulmonologist survey.The estimated annual prevalence of NTM-PD using databases is between 2.3 and 5.9 patients/100 000 inhabitants. Prevalence estimates derived from the drug dispensing databases, the hospitalisation database and the claims database were 2.3, 5.9, 3.5 and 4.5/100 000 inhabitants, respectively. The annual prevalence estimated in the pulmonologist survey was between 6.2 and 9.9/100 000 inhabitants. The annual prevalence remained stable over the included period.The estimated annual prevalence of NTM-PD using databases was between 2.3 and 5.9 patients/100 000 inhabitants. Due to the possible presence of tuberculosis patients and low coverage in one dispensing database, we believe an annual prevalence of between 2.3 and 4.5 patients/100 000 inhabitants is more probable which still renders NTM-PD a serious health threat. This estimate is lower than the estimate from the pulmonologist survey, indicating physicians likely overestimate prevalence.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The epidemiology of nontuberculous mycobacterial pulmonary disease in the Netherlands

Schildkraut

Zweijpfenning

Nap³

et al. 2021

ERJ Open Res

Self Cite

View full text Add to dashboard Cite

show abstract

“…Nontuberculous mycobacterial (NTM) lung disease is a slowly progressive disease caused mainly by Mycobacterium avium complex (MAC) that are ubiquitously present in the environment (1)(2)(3)(4)(5). The increasing incidence of the disease has become a global threat; moreover, the disease varies with ethnicity, showing a higher incidence in Asian countries than in Caucasian countries (6)(7)(8)(9). Studies have reported that several human risk factors, particularly the underlying disorders predispose to NTM lung disease (1,10).…”

Section: Introductionmentioning

confidence: 99%

Genome-wide association study reveals putative bacterial risk factors for cavitary Mycobacterium avium complex lung disease

Yano

Nishiuchi

Arikawa³

et al. 2021

Preprint

View full text Add to dashboard Cite

Mycobacterium avium complex (MAC) lung disease is a slowly progressive disease, and its increasing incidence has garnered increased research interests. Cavitary MAC lung disease is associated with a higher mortality rate. Though genetic studies have unraveled the human risk factors, the role of microbial factors on pathogenesis behind the disease remains elusive. In this study, M. avium isolates were collected from sputum specimens of 109 distinct Japanese patients with or without a cavity (60 with a cavity and 49 without cavity) in a hospital located in Osaka prefecture. M. avium genomes were sequenced and searched for DNA motifs associated with cavity formation using a bacterial GWAS. Excluding known macrolide resistance mutations; cavity formation was found to be primarily associated with variants of cytochrome P450 of the CYP139 family, type I polyketide synthase Pks13, and the promoter region of an operon encoding membrane-anchored protease FtsH and folate synthesis pathway enzymes. Cavity risk variants at these three loci were frequent in the MahEastAsia2 lineage among the six lineages detected in M. avium global populations. Furthermore, the study demonstrated a correlation between the cavity risk promoter variant and increased sulfamethoxazole/trimethoprim resistance. Together, these findings suggest that natural variation in the biosynthesis and maintenance processes of M. avium membrane components influences the disease type of MAC lung disease. Although further validation is needed, the bacterial genetic markers listed in the present study could contribute to prognosis prediction based on bacterial genotyping and help develop treatment strategies in the future.

show abstract

“…Prevalența exactă a infecțiilor cu NTM nu este cunoscută, raportarea nefiind obligatorie în mai multe țări, în practica clinică uneori fiind dificilă diferențierea dintre colonizare și infecție. În ultimii ani se observă o creștere a numărului de cazuri diagnosticate cu NTM, fapt explicat atât prin ameliorarea tehnicilor de diagnostic și accesibilității acestora, cât și prin interesul sporit pentru aceste infecții [2]. Prevalența infecției cu NTM în Statele Unite ale Americii (SUA) a crescut de la 1,4 la 6,6 la 100.000 de persoane din 2004 până în 2006 [3].…”

unclassified

“…Similar a fost semnalată creșterea prevalenței NTM în Anglia, Țara Galilor și Irlanda de Nord de la 0,9 la 2,9/100.000 de locuitori din 1995 până în 2006 [2]. În Republica Moldova nu există registre de monitorizare și declarare oficială a cazurilor cu infecții NTM, doar unele raportări de cazuri publicate de cercetătorii în domeniu [4].…”

unclassified

Nontuberculous mycobacteria and bronchiectasis

Munteanu¹,

Botnaru²

2021

BulMed

View full text Add to dashboard Cite

Nontuberculous mycobacterial pulmonary disease is an emerging multidisciplinary problem during the last decades, despite the lack of epidemiological data in most countries, including the Republic of Moldova. An increasing interest has been observed in evaluating nontuberculous mycobacteria (NTM) in patients with bronchiectasis, although the dilemma of which of these diseases comes first remains unresolved. This paper reviews several aspects of the correlations between NTM and bronchiectasis including pathogenesis, radiological features, diagnosis and management, emphasizing the necessity for clinicians to have sufficient familiarity of the mycobacteria types to provide optimal patient management.

show abstract

Epidemiology of nontuberculous mycobacterial pulmonary disease in Europe and Japan by Delphi estimation

Cited by 30 publications

References 18 publications

The epidemiology of nontuberculous mycobacterial pulmonary disease in the Netherlands

The epidemiology of nontuberculous mycobacterial pulmonary disease in the Netherlands

Genome-wide association study reveals putative bacterial risk factors for cavitary Mycobacterium avium complex lung disease

Nontuberculous mycobacteria and bronchiectasis

Contact Info

Product

Resources

About